2008 Chemotactic Cytokines Gordon Research Conference

2008年趋化细胞因子戈登研究会议

• 批准号: 7539465
• 负责人: SERGIO A. LIRA
• 金额: $ 0.3万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-14 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7539465
• 关键词: Academia; Acquired Immunodeficiency Syndrome; Animal Model; Area; Arthritis; Asthma; Atherosclerosis; Biochemical; Biological; Clinic; Communicable Diseases; Complex; Cysteine; Daily; Development; Disease; Drug Industry; Europe; European; Family; Fc Receptor; Fees; France; GTP-Binding Proteins; HIV Infections; Health; Immune system; Industry; Inflammation; Inflammatory Bowel Diseases; Leukocyte Trafficking; Malignant Neoplasms; Monoclonal Antibodies; Multiple Sclerosis; Mus; Participant; Play; Postdoctoral Fellow; Prevention; Proteins; Research; Role; Schedule; Scientist; Students; Testing; Therapeutic; Therapeutic Intervention; Travel; United States Food and Drug Administration; Work; chemokine; chemokine receptor; cost; cytokine; innovation; man; neutralizing antibody; posters; programs; receptor; social; symposium; tool

DESCRIPTION (provided by applicant): Chemokines are a family of approximately 50 proteins that differ from other cytokines in that they possess a distinctive biochemical hallmark in the form of conserved cysteine residues and act on G protein-coupled seven transmembrane (7TM) spanning receptors. Their principal role is that of directing leukocyte trafficking in the body, and they are thus pivotal to development and the establishment of the immune system. However their excessive activity results in the establishment of inflammation and through studies in animal models using tools such as genetically modified mice, neutralizing antibodies and receptor antagonists, chemokines have been shown to play a role in diseases such as asthma, atherosclerosis, multiple sclerosis, inflammatory bowel disorder and arthritis, as well as many others. They have also been shown to play a role in diseases such as cancer and infectious diseases such as AIDS, where they appear to play complex roles beyond inflammation. Since 7TM receptors are one of the cornerstones of the pharmaceutical industry, they provide a very attractive target for therapeutic intervention, and chemokine-focused programs are now moving into the clinic. Importantly 2007 witnessed the first approval by the FDA for a chemokine receptor antagonist for the prevention of HIV infection. They are also suitable targets for biological therapeutics, and again monoclonal antibodies are currently under testing in man. Thus the chemokine field attracts scientists from both academia and industry, and the Gordon Research Conference on Chemotactic Cytokines provides an ideal forum for direct exchange of ideas, and challenging discussion. The conference is scheduled to be held in Aussois, France, from 21-26 September 2008. It will be limited to 160 participants, and speakers are selected to provide a forum for innovative discussion. In addition the conference will allow students and postdoctoral fellows the opportunity to expose their work and to have informal discussions with leading scientists in this area. This will be achieved, in part, through the dedicated poster sessions and the daily social program. Since the conference is held in Europe, we expect a large European attendance, but we hope to attract a substantial participation from the US. We therefore request support to cover the costs for travel and/or conference fees at the European venue. The Health relatedness of this application is that chemokines have been shown to play a role in diseases such as asthma, atherosclerosis, multiple sclerosis, inflammatory bowel disorder and arthritis, as well as many others. They have also been shown to play a role in diseases such as cancer and infectious diseases such as AIDS, where they appear to play complex roles beyond inflammation. Since 7TM receptors are one of the cornerstones of the pharmaceutical industry, they provide a very attractive target for therapeutic intervention, and chemokine-focused programs are now moving into the clinic. Importantly 2007 witnessed the first approval by the FDA for a chemokine receptor antagonist for the prevention of HIV infection. They are also suitable targets for biological therapeutics, and again monoclonal antibodies are currently under testing in man.

描述（由申请人提供）： 趋化因子是一个由大约 50 种蛋白质组成的家族，与其他细胞因子不同，它们具有保守半胱氨酸残基形式的独特生化特征，并作用于 G 蛋白偶联七跨膜 (7TM) 跨膜受体。它们的主要作用是指导体内白细胞的运输，因此对于免疫系统的发育和建立至关重要。然而，它们的过度活性会导致炎症的产生，通过使用转基因小鼠、中和抗体和受体拮抗剂等工具对动物模型进行研究，趋化因子已被证明在哮喘、动脉粥样硬化、多发性硬化、炎症性肠病和关节炎等疾病以及许多其他疾病中发挥作用。它们还被证明在癌症等疾病和艾滋病等传染病中发挥作用，它们似乎在炎症之外发挥着复杂的作用。由于 7TM 受体是制药行业的基石之一，因此它们为治疗干预提供了非常有吸引力的靶标，并且以趋化因子为重点的项目现已进入临床。重要的是，2007 年 FDA 首次批准了趋化因子受体拮抗剂用于预防 HIV 感染。它们也是生物治疗的合适靶点，单克隆抗体目前正在人体中进行测试。因此，趋化因子领域吸引了来自学术界和工业界的科学家，戈登趋化细胞因子研究会议为直接交流思想和富有挑战性的讨论提供了一个理想的论坛。会议定于2008年9月21日至26日在法国Aussois举行。会议人数限制在160人，并选择发言人为创新讨论提供论坛。此外，会议还将让学生和博士后研究员有机会展示他们的工作并与该领域的领先科学家进行非正式讨论。这将部分通过专门的海报会议和日常社交活动来实现。由于会议在欧洲举行，我们预计会有大量欧洲与会者，但我们希望吸引美国的大量参与。因此，我们请求支持来支付欧洲场地的差旅费和/或会议费。该应用与健康相关的是，趋化因子已被证明在哮喘、动脉粥样硬化、多发性硬化症、炎症性肠病和关节炎以及许多其他疾病中发挥作用。它们还被证明在癌症等疾病和艾滋病等传染病中发挥作用，它们似乎在炎症之外发挥着复杂的作用。由于 7TM 受体是制药行业的基石之一，因此它们为治疗干预提供了非常有吸引力的靶标，并且以趋化因子为重点的项目现已进入临床。重要的是，2007 年 FDA 首次批准了趋化因子受体拮抗剂用于预防 HIV 感染。它们也是生物治疗的合适靶点，单克隆抗体目前正在人体中进行测试。